Skip to main content

Table 2 Summary of results of clinical trials with combinations of anti-PD-1/PD-L1 with immunotherapy

From: Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

Study name/code (NCT) Study phase Type of Cancer Treatment Patients evaluated for response Time to first tumor assessment (weeks) ORR by RECIST 1.1 criteria ORR by immune-related response criteria Patients treated beyond progression Response rate after initial PD First author and date of publication
102,323
(NCT02523469)
1b NSCLC Nivolumab plus ALT-803 [IL-15 superagonist] 21 6 6 (28.6%) Not reported Not reported 1 (4.8%) Wrangle 2018 [69]
ABC
(NCT02374242)
2 Melanoma Nivolumab plus ipilimumab 35 12 16–17 (46–57%)a Not reported 21 (60.0%) 4 (11.4%) Long 2018 [70]
Alliance A091401
(NCT02500797)
2 Sarcoma Nivolumab plus ipilimumab 38 6 6 (15.8%) Not reported 8 (21.1%) 1 (2.6%) D’Angelo 2018 [16]
CheckMate-004
(NCT01024231)
1 Melanoma Nivolumab plus ipilimumab 52 8 21 (40.4%) Not reported Not reported 4 (7.7%) Wolchock 2013 [24]
CheckMate 032
(NCT01928394)
1/2 Small-cell lung carcinoma Nivolumab plus ipilimumab 118 6 25 (21.2%) Not reported 21 (17.8%) Not reported Antonia 2016 [30]
CheckMate-067
(NCT01844505)
3 Melanoma Nivolumab plus ipilimumab 314 12 183 (58.3%) Not reported 62 (19.8%) Not reported Wolchok 2017 [36]
D4190C00006
(NCT02000947)
1b NSCLC Durvalumab plus tremelimumab 63 8 11 (17.5%) Not reported Not reported 2 (3.2%) Antonia 2016 [71]
J1L-AM-JZGA
(NCT02009449)
1b Advanced solid tumours Pegilodecakin plus anti-PD-1 96 8 Not reported 29 (30.2%) Not reported Not reported Naing 2019 [72]
NIBIT-MESO-1
(NCT02588131)
2 Mesothelioma Durvalumab plus tremelimumab 40 12 Not reported 11 (27.5%) 13 (32.5%) 1 (2.5%) Calabrò 2018 [73]
  1. Abbreviations: NCT ClinicalTrials.gov Identifier, NSCLC non-small-cell lung carcinoma, ORR overall response rate, PD progressive disease
  2. a Intracranial and extracranial response rate, respectively